ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > B7-H4

B7-H4

概要

Name:V-set domain-containing T-cell activation inhibitor 1
Target Synonym:V-Set Domain-Containing T-Cell Activation Inhibitor 1,Immune costimulatory protein B7-H4,B7h.5,B7 homolog 4,T-cell costimulatory molecule B7x,V-Set Domain Containing T Cell Activation Inhibitor 1,B7X,B7 Family Member, H4,T Cell Costimulatory Molecule B7x,B7S1,B7 Superfamily Member 1,VCTN1,PRO1291,FLJ22418,B7H4,B7-H4,Protein B7S1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Phase 2 Clinical

製品リスト製品比較と製品注文

ACRO Quality

生物活性データの一部

CHEK-ATP126-Cell-based assay
 B7-H4 FACS

Expression analysis of human B7-H4 on HEK293/Human B7-H4 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human B7-H4 Stable Cell Line or negative control cell using PE-labeled anti-human B7-H4 antibody.

B74-C52H8-SPR
 B7-H4 SPR

Anti-B7-H4 antibody, Human IgG1 captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Canine B7-H4, His Tag (Cat. No. B74-C52H8) with an affinity constant of 8.59 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

B74-R52H9-ELISA
 B7-H4 ELISA

Immobilized Rat B7-H4, His Tag (Cat. No. B74-R52H9) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H4 Antibody, Human IgG1 with a linear range of 0.1-8 ng/mL (QC tested).

カスタマーレビュー

Synonym Name

B7-H4,VTCN1,B7S1,B7h.5

Background

V-set domain-containing T-cell activation inhibitor 1 (VTCN1) is also known as Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, B7H4, which belongs to the immunoglobulin superfamily and BTN/MOG family. VTCN1 contains two Ig-like V-type (immunoglobulin-like) domains. The expression of VTCN1 is up-regulated by IL6 and IL10 and is inhibited by GM-CSF and IL4 on antigen-presenting cells (APCs). VTCN1 / B7-H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. VTCN1 involved in promoting epithelial cell transformation.

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Alsevalimab FPA-150 Phase 1 Clinical Five Prime Therapeutics Inc Ovarian Neoplasms; Solid tumours; Breast Neoplasms; Endometrial Neoplasms Details
AZD-8205 AZD-8205 Phase 2 Clinical Astrazeneca Plc Ovarian Neoplasms; Biliary Tract Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Endometrial Neoplasms; Neoplasm Metastasis Details
GEN-1047 GEN-1047 Phase 2 Clinical Genmab A/S Carcinoma, Non-Small-Cell Lung Details
SGN-B7H4V SGN-B-7H-4V; SGNB-7H4V; SGNB-7H-4V; SGN-B7H4V Phase 1 Clinical Seagen Inc Ovarian Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Adenoid Cystic; Breast Neoplasms; Cholangiocarcinoma; Peritoneal Neoplasms; Gallbladder Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details
NC-762 NC-762 Phase 2 Clinical Nextcure Inc Ovarian Neoplasms; Solid tumours; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
HS-20089 HS-20089 Phase 2 Clinical Shanghai Hansoh Biomedical Co Ltd Ovarian Neoplasms; Solid tumours; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms Details
XKH-002 XKH-002; XKH002 Phase 1 Clinical Beijing Kanova Biomedical Technology Co Ltd, Suzhou Kanova Biopharmaceutical Co Ltd Solid tumours; Neoplasms Details
XMT-1660 XMT-1660 Phase 1 Clinical Mersana Therapeutics Inc Ovarian Neoplasms; Abdominal Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms Details
HBM-7008 HBM7008; HBM-7008; R-7008 Phase 1 Clinical Harbour Biomed Solid tumours Details

This web search service is supported by Google Inc.

totopphone